Skip to main content

MDS 2017

  • Day 1
  • Day 2
  • Day 3
  • Day 4
  • Agenda

Allo-HSCT for patients aged 60 years or older?with MDS in Japan

May 6, 2017August 13, 2017 liorco70

http://d22fjzb79sfamb.cloudfront.net/MDS2017/fri/1500%20-%201630/Fri%201600.mp4

H. Itonaga (Japan)

Post navigation

New stem cell donor sources and regimens for transplantation
Chronic GVHD could ameliorate the adverse impact of somatic mutations in patients with MDS and Hematopoietic Stem Cell Transplantation

Day 3

Plenary Session: SINGULAR SUBTYPES OF MDS

  • 08:30 Benjamin Levine Ebert (USA)
  • 08:50 Ghulam J. Mufti (United Kingdom)
  • 09:10 Charlotte Niemeyer (Germany)
  • 09:45 T. Radivoyevitch (USA)

Plenary Session: THERAPY-1: CURRENT OPTIONS

  • 10:30 Pierre Fenaux (France)
  • 10:50 Aristoteles Giagounidis (Germany)
  • 11:10 Mikkael Sekeres (USA)
  • 11:30 P. Fenaux (France)
  • 11:45 M. Dickinson (Australia)

Plenary Session: THERAPY-2: NEW DEVELOPMENTS

  • 12:00 Lionel Ades (France)
  • 12:20 Guillermo Garcia-Manero (USA)
  • 13:00 E.M. Stein (USA)
  • 13:15 G. Montalban-Bravo (USA)

Plenary Session: THERAPY-3: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

  • 15:00 Theo De Witte (The Netherlands)
  • 15:20 Charles Craddock (United Kingdom)
  • 15:40 David Valcarcel (Spain)
  • 16:00 H. Itonaga (Japan)
  • 16:15 J.C. Caballero Berrocal (Spain)
sparkling Theme by Colorlib Powered by WordPress